PMID- 23101661
OWN - NLM
STAT- MEDLINE
DCOM- 20140210
LR  - 20190116
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 54
IP  - 7
DP  - 2013 Jul
TI  - Risk of second malignant neoplasms after cyclophosphamide-based chemotherapy with 
      or without radiotherapy for non-Hodgkin lymphoma.
PG  - 1396-404
LID - 10.3109/10428194.2012.743657 [doi]
AB  - Relatively little information is available on quantitative risks of 
      therapy-induced second malignant neoplasm (SMN) in patients with non-Hodgkin 
      lymphoma (NHL). A nested case-control study was conducted in a cohort of 3412 
      patients treated for NHL between 1990 and 2006, including 118 patients with SMN 
      and 472 controls. Risks of leukemia/lung/breast/colorectal and bladder cancer 
      were higher in NHL compared with the general population. A higher risk of 
      leukemia was restricted to patients given a cumulative dose of cyclophosphamide 
      more than 11 250 mg/m(2). However, no significant association was found between 
      SMN risk with rituximab, fludarabine, anthracyclines, epipodophyllotoxins and 
      platinum, respectively. In combined modality treatment, involved- fi eld radiation 
      therapy (IFRT) had a higher risk for second solid cancers as compared to 
      involved-nodal radiation therapy (INRT). For patients receiving radiation doses 
      exceeding 40 Gy, the risk of lung cancer and breast cancer was increased. In 
      conclusion, we found that cyclophosphamide-based therapy increased the risk of 
      SMN in NHL. Leukemia risk was linked with high-dose cyclophosphamide. A received 
      larger radiation field or higher radiation dose also could be an important risk 
      factor for the development of SMN.
FAU - Xu, Yuanlin
AU  - Xu Y
AD  - Department of Lymphoma, Tianjin Medical University Cancer Hospital, Sino-US 
      Center for Lymphoma and Leukemia, Tianjin Key Laboratory of Cancer Prevention and 
      Therapy, Tianjin, China.
FAU - Wang, Huaqing
AU  - Wang H
FAU - Zhou, Shiyong
AU  - Zhou S
FAU - Yu, Man
AU  - Yu M
FAU - Wang, Xianhuo
AU  - Wang X
FAU - Fu, Kai
AU  - Fu K
FAU - Qian, Zhengzi
AU  - Qian Z
FAU - Zhang, Huilai
AU  - Zhang H
FAU - Qiu, Lihua
AU  - Qiu L
FAU - Liu, Xianming
AU  - Liu X
FAU - Wang, Ping
AU  - Wang P
LA  - eng
PT  - Journal Article
DEP - 20121126
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 8N3DW7272P (Cyclophosphamide)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*adverse effects/therapeutic use
MH  - Case-Control Studies
MH  - Child
MH  - Child, Preschool
MH  - Cyclophosphamide/administration & dosage/*adverse effects
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Lymphoma, Non-Hodgkin/diagnosis/drug therapy/radiotherapy
MH  - Male
MH  - Middle Aged
MH  - Neoplasms, Second Primary/*epidemiology/*etiology
MH  - Radiotherapy/*adverse effects
MH  - Radiotherapy Dosage
MH  - *Risk
MH  - Young Adult
EDAT- 2012/10/30 06:00
MHDA- 2014/02/11 06:00
CRDT- 2012/10/30 06:00
PHST- 2012/10/30 06:00 [entrez]
PHST- 2012/10/30 06:00 [pubmed]
PHST- 2014/02/11 06:00 [medline]
AID - 10.3109/10428194.2012.743657 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2013 Jul;54(7):1396-404. doi: 10.3109/10428194.2012.743657. Epub 
      2012 Nov 26.